Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib Dose Finding Study Assessing Safety and Activity of [177Lu]Lu-NeoB in Combination With Radiotherapy (RT) and Temozolomide (TMZ) in Subjects With Newly Diagnosed Glioblastoma and as a Single Agent in Recurrent Glioblastoma

NCT05739942 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT05739942
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05739942 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib Dose Finding Study Assessing Safety and Activity of [177Lu]Lu-NeoB in Combination With Radiotherapy (RT) and Temozolomide (TMZ) in Subjects With Newly Diagnosed Glioblastoma and as a Single Agent in Recurrent Glioblastoma
Lead sponsor
Novartis Pharmaceuticals
Phase
Phase 1
Overall status
Active, not recruiting
Start date
May 15, 2024
Completion date
August 10, 2027
Enrollment
42 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

newly diagnosed and recurrent glioblastoma